Indivior Pharmaceuticals, Inc. INDV Business Segments
| FY'25 | FY'24 | FY'23 | ||
|---|---|---|---|---|
| Net revenue by Product | ||||
| PERSERIS | $23M-43.9% | $41M-2.4% | $42M+50.0% | |
| Sublingual & other | $226M-9.2% | $249M-11.7% | $282M-12.7% | |
| SUBLOCADE | $856M+13.2% | $756M+20.0% | $630M+54.4% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Indivior Pharmaceuticals, Inc. break its business down?
- Indivior Pharmaceuticals, Inc. (INDV) reports net revenue by product across 3 parts — PERSERIS, Sublingual & other and SUBLOCADE. Each is extracted from the segment footnotes and tracked over time.
- Where does Indivior Pharmaceuticals, Inc. 's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Indivior Pharmaceuticals, Inc. 's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.